Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Annals of Surgical Oncology
Published in: Annals of Surgical Oncology 3/2011

01-03-2011 | Translational Research and Biomarkers

Expression and Clinical Significance of Hepatoma-Derived Growth Factor as a Prognostic Factor in Human Hilar Cholangiocarcinoma

Authors: Yan-feng Liu, MD, Rui Zhao, MD, Sen Guo, MD, Xian-qiang Wang, MD, Pei-long Lian, MD, Yue-guang Chen, MD, Ke-sen Xu, MD

Published in: Annals of Surgical Oncology | Issue 3/2011

Login to get access

Abstract

Background

Overexpressions of hepatoma-derived growth factor (HDGF) and vascular endothelial growth factor (VEGF) play important roles in the development and progression of cancers. This study investigates the expression of HDGF combined with VEGF, their correlation with clinicopathologic features, and their prognosis in human hilar cholangiocarcinoma.

Materials and Methods

The expressions of HDGF and VEGF were analyzed by immunohistochemistry using the streptavidin peroxidase complex method for 58 patients with hilar cholangiocarcinoma receiving surgery. Their correlation with clinicopathologic features was then investigated. The relationships between them and the survival time of patients were retrospectively analyzed.

Results

HDGF and VEGF were positively expressed in 27 (46.6%) and 42 (72.4%) patients, respectively. HDGF and VEGF had a positive correlation (r = 0.370, P = 0.004) in the Spearman rank correlation analysis. HDGF expression was associated with gender and histological type. Patients with positive HDGF expression had a significantly poorer overall survival rate than those with negative HDGF expression (35.7 vs. 73.3%, P = 0.003). Multivariate analysis showed that HDGF expression is an independent prognostic factor.

Conclusions

HDGF expression significantly correlates with VEGF expression and is a valuable prognostic factor for human hilar cholangiocarcinoma.
Literature
1.
Khan SA, Thomas HC, Davidson BR, Taylor-Robinson SD. Cholangiocarcinoma. Lancet. 2005;366:1303–14.PubMedCrossRef
2.
Ortner MA, Dorta G. Technology insight: Photodynamic therapy for cholangiocarcinoma. Nat Clin Pract Gastroenterol Hepatol. 2006;3:459–67.PubMedCrossRef
3.
Zhang BY, Lu Y, Dong Q, Sun CD, Mu P. Surgical treatment and prognostic analysis of 93 cases of hilar cholangiocarcinoma. Am J Med Sci. 2010;339:221–4.PubMedCrossRef
4.
Bold RJ, Goodnight JE Jr. Hilar cholangiocarcinoma: surgical and endoscopic approaches. Surg Clin North Am. 2004;84:525–42.PubMedCrossRef
5.
Oikarinen H. Diagnostic imaging of carcinomas of the gallbladder and the bile ducts. Acta Radiol. 2006;47:345–58.PubMedCrossRef
6.
7.
Jarnagin WR, Shoup M. Surgical management of cholangiocarcinoma. Semin Liver Dis. 2004;24:189–99.PubMedCrossRef
8.
Nakamura H, Izumoto Y, Kambe H, Kuroda T, Mori T, Kawamura K, et al. Molecular cloning of complementary DNA for a novel human hepatoma-derived growth factor. Its homology with high mobility group-1 protein. J Biol Chem. 1994;269:25143–9.PubMed
9.
Nakamura H, Kambe H, Egawa T, Kimura Y, Ito H, Hayashi E, et al. Partial purification and characterization of human hepatoma-derived growth factor. Clin Chim Acta. 1989;183:273–84.PubMedCrossRef
10.
Everett AD. Identification, cloning, and developmental expression of hepatoma-derived growth factor in the developing rat heart. Dev Dyn. 2001;222:450–8.PubMedCrossRef
11.
Wanschura S, Schoenmakers EF, Huysmans C, Bartnitzke S, Van de Ven WJ, Bullerdiek J. Mapping of the gene encoding the human hepatoma-derived growth factor (HDGF) with homology to the high-mobility group (HMG)-1 protein to Xq25. Genomics. 1996;32:298–300.PubMedCrossRef
12.
Everett AD, Bushweller J. Hepatoma derived growth factor is a nuclear targeted mitogen. Curr Drug Targets. 2003;4:367–71.PubMedCrossRef
13.
Everett AD, Stoops T, McNamara CA. Nuclear targeting is required for hepatoma-derived growth factor-stimulated mitogenesis in vascular smooth muscle cells. J Biol Chem. 2001;276:37564–8.PubMedCrossRef
14.
Kishima Y, Yamamoto H, Izumoto Y, Yoshida K, Enomoto H, Yamamoto M, et al. Hepatoma-derived growth factor stimulates cell growth after translocation to the nucleus by nuclear localization signals. J Biol Chem. 2002;277:10315–22.PubMedCrossRef
15.
Zhou Z, Yamamoto Y, Sugai F, Yoshida K, Kishima Y, Sumi H, et al. Hepatoma-derived growth factor is a neurotrophic factor harbored in the nucleus. J Biol Chem. 2004;279:27320–6.PubMedCrossRef
16.
Everett AD, Lobe DR, Matsumura ME, Nakamura H, McNamara CA. Hepatoma-derived growth factor stimulates smooth muscle cell growth and is expressed in vascular development. J Clin Invest. 2000;105:567–75.PubMedCrossRef
17.
Ooi B, Mukhopadhyay A, Masilamani J, Do DV, Lim CP, Cao XM, et al. Hepatoma-derived growth factor and its role in keloid pathogenesis. J Cell Mol Med. 2010;14:1328–37.PubMedCrossRef
18.
Meng J, Xie W, Cao L, Hu C, Zhe Z. shRNA targeting HDGF suppressed cell growth and invasion of squamous cell lung cancer. Acta Biochim Biophys Sin (Shanghai). 2010;42:52–7.CrossRef
19.
Tsang TY, Tang WY, Tsang WP, Co NN, Kong SK, Kwok TT. Mechanistic study on growth suppression and apoptosis induction by targeting hepatoma-derived growth factor in human hepatocellular carcinoma HepG2 cells. Cell Physiol Biochem. 2009;24:253–62.PubMedCrossRef
20.
Yamamoto S, Tomita Y, Hoshida Y, Takiguchi S, Fujiwara Y, Yasuda T, et al. Expression of hepatoma-derived growth factor is correlated with lymph node metastasis and prognosis of gastric carcinoma. Clin Cancer Res. 2006;12:117–22.PubMedCrossRef
21.
Uyama H, Tomita Y, Nakamura H, Nakamori S, Zhang B, Hoshida Y, et al. Hepatoma-derived growth factor is a novel prognostic factor for patients with pancreatic cancer. Clin Cancer Res. 2006;12:6043–8.PubMedCrossRef
22.
Ren H, Tang X, Lee JJ, Feng L, Everett AD, Hong WK, et al. Expression of hepatoma-derived growth factor is a strong prognostic predictor for patients with early-stage non-small-cell lung cancer. J Clin Oncol. 2004;22:3230–7.PubMedCrossRef
23.
Yoshida K, Tomita Y, Okuda Y, Yamamoto S, Enomoto H, Uyama H, et al. Hepatoma-derived growth factor is a novel prognostic factor for hepatocellular carcinoma. Ann Surg Oncol. 2006;13:159–67.PubMedCrossRef
24.
Hu TH, Lin JW, Chen HH, Liu LF, Chuah SK, Tai MH. The expression and prognostic role of hepatoma-derived growth factor in colorectal stromal tumors. Dis Colon Rectum. 2009;52:319–26.PubMed
25.
Yamamoto S, Tomita Y, Hoshida Y, Morii E, Yasuda T, Doki Y, et al. Expression level of hepatoma-derived growth factor correlates with tumor recurrence of esophageal carcinoma. Ann Surg Oncol. 2007;14:2141–9.PubMedCrossRef
26.
Chang KC, Tai MH, Lin JW, Wang CC, Huang CC, Hung CH, et al. Hepatoma-derived growth factor is a novel prognostic factor for gastrointestinal stromal tumors. Int J Cancer. 2007;121:1059–65.PubMedCrossRef
27.
Hu TH, Huang CC, Liu LF, Lin PR, Liu SY, Chang HW, et al. Expression of hepatoma-derived growth factor in hepatocellular carcinoma. Cancer. 2003;98:1444–56.PubMedCrossRef
28.
Okuda Y, Nakamura H, Yoshida K, Enomoto H, Uyama H, Hirotani T, et al. Hepatoma-derived growth factor induces tumorigenesis in vivo through both direct angiogenic activity and induction of vascular endothelial growth factor. Cancer Sci. 2003;94:1034–41.PubMedCrossRef
29.
Zhang J, Ren H, Yuan P, Lang W, Zhang L, Mao L. Down-regulation of hepatoma-derived growth factor inhibits anchorage-independent growth and invasion of non-small cell lung cancer cells. Cancer Res. 2006;66:18–23.PubMedCrossRef
30.
Everett AD, Narron JV, Stoops T, Nakamura H, Tucker A. Hepatoma-derived growth factor is a pulmonary endothelial cell-expressed angiogenic factor. Am J Physiol Lung Cell Mol Physiol. 2004;286:L1194–201.PubMedCrossRef
31.
Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 1989;246:1306–9.PubMedCrossRef
32.
Fava G, Demorrow S, Gaudio E, Franchitto A, Onori P, Carpino G, et al. Endothelin inhibits cholangiocarcinoma growth by a decrease in the vascular endothelial growth factor expression. Liver Int. 2009;29:1031–42.PubMedCrossRef
33.
Mancino A, Mancino MG, Glaser SS, Alpini G, Bolognese A, Izzo L, et al. Estrogens stimulate the proliferation of human cholangiocarcinoma by inducing the expression and secretion of vascular endothelial growth factor. Dig Liver Dis. 2009;41:156–63.PubMedCrossRef
34.
Benckert C, Jonas S, Cramer T, Von Marschall Z, Schäfer G, Peters M, et al. Transforming growth factor beta 1 stimulates vascular endothelial growth factor gene transcription in human cholangiocellular carcinoma cells. Cancer Res. 2003;63:1083–92.PubMed
35.
Yoshikawa D, Ojima H, Iwasaki M, Hiraoka N, Kosuge T, Kasai S, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98:418–25.PubMedCrossRef
36.
Hida Y, Morita T, Fujita M, Miyasaka Y, Horita S, Fujioka Y, et al. Vascular endothelial growth factor expression is an independent negative predictor in extrahepatic biliary tract carcinomas. Anticancer Res. 1999;19:2257–60.PubMed
37.
Weidner N. Current pathologic methods for measuring intratumoral microvessel density within breast carcinoma and other solid tumors. Breast Cancer Res Treat. 1995;36:169–80.PubMedCrossRef
38.
Yano T, Tanikawa S, Fujie T, Masutani M, Horie T. Vascular endothelial growth factor expression and neovascularisation in non-small cell lung cancer. Eur J Cancer. 2000;36:601–9.PubMedCrossRef
39.
Klatskin G. Adenocarcinoma of the hepatic duct at its bifurcation within the porta hepatis. An unusual tumor with distinctive clinical and pathological features. Am J Med. 1965;38:241–56.PubMedCrossRef
40.
Ito F, Cho CS, Rikkers LF, Weber SM. Hilar cholangiocarcinoma: current management. Ann Surg. 2009;250:210–8.PubMedCrossRef
41.
Riley RD, Abrams KR, Sutton AJ, Lambert PC, Jones DR, Heney D, et al. Reporting of prognostic markers: current problems and development of guidelines for evidence-based practice in the future. Br J Cancer. 2003;88:1191–8.PubMedCrossRef
42.
Oliver JA, Al-Awqati Q. An endothelial growth factor involved in rat renal development. J Clin Invest. 1998;102:1208–19.PubMedCrossRef
43.
Mao J, Xu Z, Fang Y, Wang H, Xu J, Ye J, et al. Hepatoma-derived growth factor involved in the carcinogenesis of gastric epithelial cells through promotion of cell proliferation by Erk1/2 activation. Cancer Sci. 2008;99:2120–7.PubMedCrossRef
Metadata
Title
Expression and Clinical Significance of Hepatoma-Derived Growth Factor as a Prognostic Factor in Human Hilar Cholangiocarcinoma
Authors
Yan-feng Liu, MD
Rui Zhao, MD
Sen Guo, MD
Xian-qiang Wang, MD
Pei-long Lian, MD
Yue-guang Chen, MD
Ke-sen Xu, MD
Publication date
01-03-2011
Publisher
Springer-Verlag
Published in
Annals of Surgical Oncology / Issue 3/2011
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI
https://doi.org/10.1245/s10434-010-1303-x

Other articles of this Issue 3/2011

Annals of Surgical Oncology 3/2011 Go to the issue

Hepatobiliary Tumors

Regenerative Nodular Hyperplasia of the Liver Related to Chemotherapy: Impact on Outcome of Liver Surgery for Colorectal Metastases

Bone and Soft Tissue Sarcomas

Myxofibrosarcoma: Prognostic Factors and Survival in a Series of Patients Treated at a Single Institution

Healthcare Policy and Outcomes

Quality Measurement in Cancer Care Delivery

Translational Research and Biomarkers

Regarding: Epithelial-Mesenchymal Transition Induced by Hepatitis C Virus Core Protein in Cholangiocarcinoma

Gynecologic Oncology

Radiation-Induced Bowel Complications: Laparoscopic Versus Open Staging of Gynecologic Malignancy

Colorectal Cancer

Outcome Standards for an Organ Preservation Strategy in Stage II and III Rectal Adenocarcinoma after Neoadjuvant Chemoradiation